Omnicell (OMCL)
Automates medication dispensing, pharmacy compounding, and outpatient medication workflows.
Something off on this page? Send us feedback.
Sells automated dispensing cabinets, central-pharmacy and IV-compounding robotics, cloud software, consumables, and expert services across hospital and outpatient pharmacy settings. Revenue combines equipment and license sales with recurring technical support, subscriptions, and consumables, while remaining concentrated in the United States.
Builds medication-management infrastructure for hospitals, health systems, and pharmacies. Point-of-care dispensing cabinets, central-pharmacy robotics, IV-compounding automation, and the OmniSphere cloud platform connect medication storage, preparation, distribution, inventory, and diversion monitoring.
Extends beyond inpatient workflows through Specialty Pharmacy Services and 340B administration, the EnlivenHealth retail-pharmacy platform, and medication-adherence packaging and automation. Pairs connected hardware with cloud analytics and onsite or remote specialists, while earning recurring revenue from consumables, technical support, SaaS, and expert services.
Most revenue comes from the United States. Results depend on healthcare providers' capital and operating budgets, lengthy purchasing and installation cycles, reliable hardware and cloud software, access to specialty-drug networks, limited-source components, and evolving pharmacy, medical-device, privacy, and 340B rules.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 31, 2026 | Keybanc | Reiterate | Rating: —Target: $70 | Target: $65 |
| Jul 31, 2026 | Wells Fargo | Reiterate | Rating: —Target: $52 | Target: $50 |
| Apr 29, 2026 | Craig-Hallum | Target | Target: — | Target: $55 |
| Apr 28, 2026 | KeyBanc | Target | Target: $60 | Target: $70 |
| Mar 13, 2026 | UBS | Target | Target: $53 | Target: $60 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $307.0M · Total debt $200.0M · Total assets $2.00B · Shareholders' equity $1.29B
- Revenue
- $312.2M
- Operating income
- $32.4M
- Net income
- $24.3M
No dividends on record.
| Institutions | ≈ 105.25% | 48.01M shares | |
|---|---|---|---|
| 313 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 3.47% | 1.58M shares | |
| 14 holders · as of Aug 18, 2026 | |||
| Adds to | 108.72% | ||
45.61M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 108.72%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 16.53% | 7.54M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 6.91% | 3.15M | as of Jun 30, 2026 |
Wellington Management Group LLPInstitution | 5.92% | 2.70M | as of Jun 30, 2026 |
Dimensional Fund Advisors LPInstitution | 5.38% | 2.45M | as of Jun 30, 2026 |
State Street CorpInstitution | 4.57% | 2.09M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 17, 2026 | Nnamdi Njoku | officer: President & COO | −3,083 | $36.85 |
| Jul 15, 2026 | Randall A. Lipps | director, officer: CHAIRMAN, CEO | −10,000 | $47.00 |
| May 18, 2026 | Corey J. Manley | officer: EVP&CHIEF LEGAL/ADMIN OFFICER | −5,025 | $43.22 |
| May 18, 2026 | Nnamdi Njoku | officer: EVP, Chief Operating Officer | −3,090 | $43.22 |
| Mar 16, 2026 | Corey J. Manley | officer: EVP&CHIEF LEGAL/ADMIN OFFICER | −7,405 | $34.69 |
- BD
Direct Pyxis rival in hospital and pharmacy automation
- McKesson
Pharmacy services, 340B, and workflow adjacency
- Baxter International
IV workflow and pharmacy-preparation competitor
- Cencora
Specialty pharmacy and 340B services competitor
- Cardinal Health
Pharmacy distribution and specialty-services competitor
- ICU Medical
IV compounding automation rival around hazardous drugs
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Omnicell | $32.88 | +1.37% | $1.47B | 38.4 | 18.3 | 1.2 | +7.5% |
| BD | $181.76 | +0.59% | $49.79B | 54.4 | 13.7 | 2.4 | −9.6% |
| McKesson | $888.83 | +0.27% | $103.79B | 23.7 | 19.2 | 0.3 | +7.7% |
| Baxter International | $23.79 | +3.75% | $11.85B | — | 11.3 | 1.0 | +5.3% |
| Cencora | $315.94 | −0.17% | $61.58B | 23.5 | 16.3 | 0.2 | +5.1% |
| Cardinal Health | $226.30 | +0.24% | $52.87B | 31.2 | 18.1 | 0.2 | +5.8% |
| ICU Medical | $158.41 | +2.06% | $3.88B | 131.5 | 17.9 | 1.8 | −0.2% |
| Median | 31.2 | 17.1 | 0.6 | +5.2% |